VistaGen Therapeutics's market cap is currently $84.71M. The company's EPS TTM is $-1.584; its P/E ratio is ―; VistaGen Therapeutics is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is $-0.51. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Income Statement
Total Revenue	$ 1.06M	$ -227.00K	$ 1.11M	$ 1.09M	$ 0.00
Gross Profit	$ 1.06M	$ -227.00K	$ 1.11M	$ 1.09M	$ 0.00
Operating Income	$ -33.02M	$ -59.27M	$ -47.78M	$ -17.93M	$ -20.80M
EBITDA	$ -32.45M	$ -58.74M	$ -47.05M	$ -17.44M	$ -20.65M
Net Income	$ -29.36M	$ -59.25M	$ -47.76M	$ -17.93M	$ -20.77M
Balance Sheet
Cash & Short-Term Investments	$ 119.17M	$ 16.64M	$ 68.14M	$ 103.11M	$ 1.36M
Total Assets	$ 123.65M	$ 21.09M	$ 74.64M	$ 108.28M	$ 5.77M
Total Debt	$ 2.12M	$ 2.72M	$ 3.04M	$ 3.72M	$ 4.09M
Net Debt	$ -117.05M	$ -13.92M	$ -65.10M	$ -99.39M	$ 2.74M
Total Liabilities	$ 9.37M	$ 9.01M	$ 9.93M	$ 16.30M	$ 11.50M
Stockholders' Equity	$ 114.29M	$ 12.08M	$ 64.72M	$ 91.98M	$ -5.73M
Cash Flow
Free Cash Flow	$ -25.87M	$ -49.93M	$ -45.46M	$ -12.35M	$ -15.76M
Operating Cash Flow	$ -25.81M	$ -49.72M	$ -45.26M	$ -12.07M	$ -15.76M
Investing Cash Flow	$ -61.00K	$ -740.30K	$ -200.40K	$ -275.40K	$ 0.00
Financing Cash Flow	$ 128.40M	$ -1.04M	$ 10.48M	$ 114.10M	$ 4.01M

Currency in USD

VistaGen Therapeutics Earnings and Revenue History

Income Statement >

VistaGen Therapeutics Debt to Assets

Balance Sheet >

VistaGen Therapeutics Cash Flow

Cash Flow >

VistaGen Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing